The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy
Chemically, retatrutide is a longacting, multireceptor incretin mimetic engineered to coactivate the glucagonlike peptide1 (GLP1R), glucosedependent insulinotropic polypeptide (GIPR), and glucagon (GCGR) receptors
According to Table 1, comprehensive experimental and observational studies reveal that GLP-1RAs do not elevate overall cancer risk, while preclinical investigations have demonstrated multiple anti-tumor mechanisms, including proliferation inhibition, apoptosis induction, and metastasis suppression
You start at 0.25 mg weekly for the first four weeks, then increase to 0.5 mg for weeks 5 through 8, then 1 mg for weeks 9 through 12, then 1.7 mg for weeks 13 through 16, and finally the maintenance dose of 2.4 mg from week 17 onward
Why is muscle preservation important during weight loss
Appropriate Dosing Times: Morning time in shower